The identification of a specific NUP214 rearrangement is fundamental to choosing an optimal therapeutic strategy: by way of example, patients with DEK::NUP214 are classified as an adverse risk group within AML and might be considered candidates for allogenic bone marrow transplantation. This evidence concerns the gene NUP214 and acute myeloid leukemia.